Taysha gene therapies receives orphan drug designation from the european commission for tsha-120 for the treatment of giant axon neuropathy (gan)

Clinical efficacy data for tsha-120 provide quantitative evidence of long-term durability across all therapeutic dose cohorts with a 10-point improvement in mean change in mfm32 by year 3 compared to estimated natural history decline of 24 points

TSHA Ratings Summary

TSHA Quant Ranking